Clear cell renal cell carcinoma (ccRCC) is the most prevalent renal malignancy in adults with generally poor prognosis. This study aimed to establish a DNA methylation-driven gene-based prognostic model for ccRCC. We collected DNA methylation and gene expression profiles of over 1500 ccRCC samples from The Cancer Genome Atlas (TCGA) dataset, four Gene Expression Omnibus (GEO) datasets, the Genotype-Tissue Expression (GTEx) dataset, and cancer cell lines from Cancer Cell Line Encyclopedia database and performed comprehensive bioinformatics analysis. As a result, a total of 31 differentially expressed methylation-driven genes (DEMDGs) were identified. After univariate Cox regression, least absolute shrinkage and selection operator, and multivariate Cox regression analyses, four (NFE2L3, HHLA2, IFI16, and ZNF582) were finally selected to construct a risk score prognostic model. The high-risk group demonstrated significantly poor prognosis than the low-risk group did in TCGA training (hazard ratio [HR] = 3.533, p < 0.001), TCGA internal, and GEO external validation datasets. Furthermore, the nomogram, including the prognostic model and clinical factors, showed promising prognostic value (HR = 5.756, p < 0.001, and area under the curve at 1 year = 0.856). In addition, the model was found to be significantly associated with drug sensitivity of eight targeted agents. These findings provided a novel and reliable four DEMDG-based prognostic model for ccRCC.
Get full access to this article
View all access options for this article.
References
1.
BarataP.C., and RiniB.I. (2017). Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin, 67, 507–524.
2.
BaylinS.B., and JonesP.A. (2011). A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer, 11, 726–734.
3.
BrayF., FerlayJ., SoerjomataramI., SiegelR.L., TorreL.A., and JemalA. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394–424.
4.
CampR.L., Dolled-FilhartM., and RimmD.L. (2004). X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res, 10, 7252–7259.
5.
CedarH., and BergmanY. (2012). Programming of DNA methylation patterns. Annu Rev Biochem, 81, 97–117.
6.
ChenL., ZhuD., FengJ., ZhouY., WangQ., FengH., et al. (2019). Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients. Cancer Cell Int 19,101.
7.
ChenZ., YanC.T., DouY., ViboolsittiseriS.S., and WangJ.H. (2013). The role of a newly identified SET domain-containing protein, SETD3, in oncogenesis. Haematologica, 98, 739–743.
8.
ChevillardG., and BlankV. (2011). NFE2L3 (NRF3): the Cinderella of the Cap‘n'Collar transcription factors. Cell Mol Life Sci, 68, 3337–3348.
9.
ChevillardG., PaquetM., and BlankV. (2011). Nfe2l3 (Nrf3) deficiency predisposes mice to T-cell lymphoblastic lymphoma. Blood, 117, 2005–2008.
10.
ChowdhuryA.M.M.A., KatohH., HatanakaA., IwanariH., NakamuraN., HamakuboT., et al. (2017). Multiple regulatory mechanisms of the biological function of NRF3 (NFE2L3) control cancer cell proliferation. Sci Rep 7,12494.
11.
ChurchT.R., WandellM., Lofton-DayC., MonginS.J., BurgerM., PayneS.R., et al. (2014). Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut, 63, 317–325.
CruickshanksH.A., McBryanT., NelsonD.M., VanderkraatsN.D., ShahP.P., van TuynJ., et al. (2013). Senescent cells harbour features of the cancer epigenome. Nat Cell Biol, 15, 1495–1506.
14.
DalglieshG.L., FurgeK., GreenmanC., ChenL., BignellG., ButlerA., et al. (2010). Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature, 463, 360–363.
15.
DawsonM.A., and KouzaridesT. (2012). Cancer epigenetics: from mechanism to therapy. Cell, 150, 12–27.
16.
EngK.H., SchillerE., and MorrellK. (2015). On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve. Oncotarget, 6, 36308–36318.
17.
EscudierB., PortaC., SchmidingerM., Rioux-LeclercqN., BexA., KhooV., et al. (2019). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol, 30, 706–720.
18.
EstellerM., and HermanJ.G. (2002). Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol, 196, 1–7.
19.
FerlayJ., Steliarova-FoucherE., Lortet-TieulentJ., RossoS., CoeberghJ.W.W., ComberH., et al. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer, 49, 1374–1403.
20.
FigueroaM.E., LugthartS., LiY., Erpelinck-VerschuerenC., DengX., ChristosP.J., et al. (2010). DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell, 17, 13–27.
21.
FujiuchiN., AglipayJ.A., OhtsukaT., MaeharaN., SahinF., SuG.H., et al. (2004). Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation. J Biol Chem, 279, 20339–20344.
22.
GevaertO. (2015). MethylMix: an R package for identifying DNA methylation-driven genes. Bioinformatics (Oxford, England), 31, 1839–1841.
23.
HanX., ZhouZ., FeiL., SunH., WangR., ChenY., et al. (2020). Construction of a human cell landscape at single-cell level. Nature, 581, 303–309.
24.
HeagertyP.J., LumleyT., and PepeM.S. (2000). Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics, 56, 337–344.
HuntleyS., BaggottD.M., HamiltonA.T., Tran-GyamfiM., YangS., KimJ., et al. (2006). A comprehensive catalog of human KRAB-associated zinc finger genes: insights into the evolutionary history of a large family of transcriptional repressors. Genome Res, 16, 669–677.
27.
JanakiramM., ShahU.A., LiuW., ZhaoA., SchoenbergM.P., and ZangX. (2017). The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7–H3. Immunol Rev, 276, 26–39.
28.
JoostenS.C., SmitsK.M., AartsM.J., MelotteV., KochA., Tjan-HeijnenV.C., et al. (2018). Epigenetics in renal cell cancer: mechanisms and clinical applications. Nat Rev Urol, 15, 430–451.
29.
KangH.-J., LeeM.-H., KangH.-L., KimS.-H., AhnJ.-R., NaH., et al. (2014). Differential regulation of estrogen receptor α expression in breast cancer cells by metastasis-associated protein 1. Cancer Res, 74, 1484–1494.
30.
KobayashiA., and WakuT. (2020). New addiction to the NRF2-related factor NRF3 in cancer cells: ubiquitin-independent proteolysis through the 20S proteasome. Cancer Sci, 111, 6–14.
31.
KochA., JoostenS.C., FengZ., de RuijterT.C., DrahtM.X., MelotteV., et al. (2018). Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncol, 15, 459–466.
32.
KolbR., LiuG.-H., JanowskiA.M., SutterwalaF.S., and ZhangW. (2014). Inflammasomes in cancer: a double-edged sword. Protein Cell, 5, 12–20.
33.
KondoY., NagaiK., NakahataS., SaitoY., IchikawaT., SuekaneA., et al. (2012). Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon-inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation. Cancer Sci, 103, 782–790.
34.
KumegawaK., MaruyamaR., YamamotoE., AshidaM., KitajimaH., TsuyadaA., et al. (2016). A genomic screen for long noncoding RNA genes epigenetically silenced by aberrant DNA methylation in colorectal cancer. Sci Rep 6,26699.
35.
KüppersR., KleinU., SchweringI., DistlerV., BräuningerA., CattorettiG., et al. (2003). Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest, 111, 529–537.
36.
MooreL.D., LeT., and FanG. (2013). DNA methylation and its basic function. Neuropsychopharmacology, 38, 23–38.
MoynihanK.D., and IrvineD.J. (2017). Roles for innate immunity in combination immunotherapies. Cancer Res, 77, 5215–5221.
39.
NickersonM.L., JaegerE., ShiY., DurocherJ.A., MahurkarS., ZaridzeD., et al. (2008). Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res, 14, 4726–4734.
40.
NielsenS.N., GrellK., NerstingJ., AbrahamssonJ., LundB., KanervaJ., et al. (2017). DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. Lancet Oncol, 18, 515–524.
41.
PanQ., WangL., ZhangH., LiangC., and LiB. (2019). Identification of a 5-gene signature predicting progression and prognosis of clear cell renal cell carcinoma. Med Sci Monit, 25, 4401–4413.
42.
ParkerW.P., ChevilleJ.C., FrankI., ZaidH.B., LohseC.M., BoorjianS.A., et al. (2017). Application of the Stage, Size, Grade, and Necrosis (SSIGN) score for clear cell renal cell carcinoma in contemporary patients. Eur Urol, 71, 665–673.
43.
RauscherG.H., KresovichJ.K., PoulinM., YanL., MaciasV., MahmoudA.M., et al. (2015). Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation. BMC Cancer 15,816.
44.
RobinsonM.D., McCarthyD.J., and SmythG.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (Oxford, England), 26, 139–140.
45.
SankinA., HakimiA.A., MikkilineniN., OstrovnayaI., SilkM.T., LiangY., et al. (2014). The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med, 3, 1485–1492.
46.
SantoniM., BerardiR., AmantiniC., BurattiniL., SantiniD., SantoniG., et al. (2014). Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. Int J Cancer, 134, 2772–2777.
SerreD., LeeB.H., and TingA.H. (2010). MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Res, 38, 391–399.
49.
SiegelR.L., MillerK.D., and JemalA. (2017). Cancer statistics, 2017. CA Cancer J Clin, 67, 7–30.
50.
SinghN.P., and VinodP.K. (2020). Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma. Mol Genet Genomics, 295, 807–824.
51.
TangL., LiouY.-L., WanZ.-R., TangJ., ZhouY., ZhuangW., et al. (2019). Aberrant DNA methylation of PAX1, SOX1 and ZNF582 genes as potential biomarkers for esophageal squamous cell carcinoma. Biomed Pharmacother 120,109488.
52.
TerlizziM., CasolaroV., PintoA., and SorrentinoR. (2014). Inflammasome: cancer's friend or foe?. Pharmacol Ther, 143, 24–33.
53.
TorreL.A., BrayF., SiegelR.L., FerlayJ., Lortet-TieulentJ., and JemalA. (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65, 87–108.
van VlodropI.J.H., JoostenS.C., De MeyerT., SmitsK.M., Van NesteL., MelotteV., et al. (2017). A Four-gene promoter methylation marker panel consisting of and predicts survival of clear cell renal cell cancer patients. Clin Cancer Res, 23, 2006–2018.
56.
WangJ., ZhaoH., DongH., ZhuL., WangS., WangP., et al. (2019). LAT, HOXD3 and NFE2L3 identified as novel DNA methylation-driven genes and prognostic markers in human clear cell renal cell carcinoma by integrative bioinformatics approaches. J Cancer, 10, 6726–6737.
57.
WiltingR.H., and DannenbergJ.-H. (2012). Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat, 15, 21–38.
58.
YanH., QiuW., Koehne de GonzalezA.K., WeiJ.-S., TuM., XiC.-H., et al. (2019). HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival. Cancer Lett, 442, 333–340.
59.
YangW., SoaresJ., GreningerP., EdelmanE.J., LightfootH., ForbesS., et al. (2013). Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res, 41, D955–D961.
60.
YangX., GaoL., and ZhangS. (2017). Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns. Brief Bioinformatics, 18, 761–773.
61.
YuG., WangL.-G., HanY., and HeQ.-Y. (2012). clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS, 16, 284–287.
62.
ZhuY., YaoS., IliopoulouB.P., HanX., AugustineM.M., XuH., et al. (2013). B7–H5 costimulates human T cells via CD28H. Nat Commun 4,2043.
63.
ZigeunerR., HuttererG., ChromeckiT., ImamovicA., Kampel-KettnerK., RehakP., et al. (2010). External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol, 57, 102–109.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
